Causes and timing of death in study population
| . | Children (n = 334) . | Adolescents (n = 61) . | Total (N = 395) . | ||
|---|---|---|---|---|---|
| First 100 d after HSCT . | After 100 d from HSCT . | First 100 d after HSCT . | After 100 d from HSCT . | ||
| Cause of death | |||||
| aGvHD | 12 | 6 | 2 | 0 | 20 |
| cGvHD | 0 | 9 | 0 | 2 | 11 |
| Hemorrhage | 3 | 1 | 2 | 0 | 6 |
| ARDS | 3 | 1 | 0 | 0 | 4 |
| Idiopathic pneumonia | 1 | 1 | 1 | 0 | 3 |
| Aspergillus pneumonia | 2 | 1 | 0 | 0 | 3 |
| Pneumocystis pneumonia | 0 | 0 | 1 | 0 | 1 |
| HCMV pneumonia | 2 | 0 | 0 | 1 | 3 |
| Bacterial infections | 6 | 6 | 2 | 0 | 14 |
| Fungal infections | 2 | 0 | 0 | 0 | 2 |
| Viral infections | 1 | 1 | 1 | 0 | 3 |
| Veno-occlusive disease | 1 | 1 | 1 | 0 | 3 |
| Multiorgan failure | 4 | 4 | 1 | 0 | 9 |
| EBV-PTLD | 2 | 0 | 0 | 0 | 2 |
| TTP | 1 | 0 | 0 | 0 | 1 |
| Total transplant-related deaths | 40 | 31 | 11 | 3 | 85 |
| Disease progression | 4 | 64 | 1 | 10 | 79 |
| Total | 44 | 95 | 12 | 13 | 164 |
| . | Children (n = 334) . | Adolescents (n = 61) . | Total (N = 395) . | ||
|---|---|---|---|---|---|
| First 100 d after HSCT . | After 100 d from HSCT . | First 100 d after HSCT . | After 100 d from HSCT . | ||
| Cause of death | |||||
| aGvHD | 12 | 6 | 2 | 0 | 20 |
| cGvHD | 0 | 9 | 0 | 2 | 11 |
| Hemorrhage | 3 | 1 | 2 | 0 | 6 |
| ARDS | 3 | 1 | 0 | 0 | 4 |
| Idiopathic pneumonia | 1 | 1 | 1 | 0 | 3 |
| Aspergillus pneumonia | 2 | 1 | 0 | 0 | 3 |
| Pneumocystis pneumonia | 0 | 0 | 1 | 0 | 1 |
| HCMV pneumonia | 2 | 0 | 0 | 1 | 3 |
| Bacterial infections | 6 | 6 | 2 | 0 | 14 |
| Fungal infections | 2 | 0 | 0 | 0 | 2 |
| Viral infections | 1 | 1 | 1 | 0 | 3 |
| Veno-occlusive disease | 1 | 1 | 1 | 0 | 3 |
| Multiorgan failure | 4 | 4 | 1 | 0 | 9 |
| EBV-PTLD | 2 | 0 | 0 | 0 | 2 |
| TTP | 1 | 0 | 0 | 0 | 1 |
| Total transplant-related deaths | 40 | 31 | 11 | 3 | 85 |
| Disease progression | 4 | 64 | 1 | 10 | 79 |
| Total | 44 | 95 | 12 | 13 | 164 |
ARDS indicates acute respiratory distress syndrome; HCMV, human cytomegalovirus; EBV-PTLD, Epstein-Barr virus–related post-transplant lymphoproliferative disease; and TTP, thrombotic thrombocytopenic purpura.